Abstract
The prognostic significance of progesterone receptor activity (PgR) with regard to the estimated relapse-free survival (RFS) was studied in 350 one-center patients with primary breast cancer. All receptor assays were performed in one laboratory; PgR levels >10 fmol/mg protein were considered positive. Univariate as well as multivariate statistical analyses were used to examine the prognostic significance of several variables. Eighty-nine of the 350 patients received adjuvant CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil). The median observation period was 69 months (range 12–125 months).
In the group of 261 patients who did not receive adjuvant CMF, the PgR-status lacked prognostic significance; only the lymph node status significantly affected the RFS (p<0.00001). In contrast, in the CMF-treated group of patients, the PgR-status was the most powerful predictor of recurrence (p<0.0001). The menopausal and the lymph-node status increased the predictive value of PgR (p<0.001). Premenopausal CMF-treated patients with PgR+ tumors had a significantly longer RFS than those with PgR− tumors (p<0.02). The present data urge the need for a reappraisal of the prognostic significance of PgR and of the mechanism of action of adjuvant chemotherapy in primary breast cancer.
References
Pichon MF, Pallud C, Brunet M, Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 40: 3357–3360, 1980
Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptor as a prognostic factor in stage II breast cancer. N Engl J Med 309: 1343–1347, 1983
Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i: 558–591, 1984
Howat JMT, Harris M, Swindell R, Barnes DM: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51: 263–270, 1985
Raemaekers JMM, Beex LVAM, Koenders AJM, Pieters GFFM, Smals AGH, Benraad ThJ, Kloppenborg PWC, and the Breast Cancer Group: Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 6: 123–131, 1985
Koenders AJ, Geurts-Moespot J, Kho KH, Benraad ThJ: Estradiol and progesterone receptor activities in stored lyophilized target tissue. J Steroid Biochem 9: 947–950, 1978
Gehan E: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 52: 203–224, 1965
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966
Cox DR: Regression models and life-tables. J R Stat Soc 34: 187–200, 1972
Dixon WJ (ed): BMDP statistical software. Berkeley California Press, 1983
Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HMT, Aitken SL, Warren R: Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63: 1271–1277, 1979
Howat JMT, Barnes DM, Harris M, Swindell R: Association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 47: 629–640, 1983
Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985–2990, 1983
Saez S, Cheix F, Asselain B: Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat 3: 345–354, 1983
Alanko A, Heinonen E, Scheinin TM, Tolppanen EM, Vihko RV: Oestrogen and progesterone receptors and disease free interval in primary breast cancer. Cancer 50: 667–672, 1984
Di Fronzo G, Cappelletti V, Coradini D, Ronchi E, Scavone G: Prognostic significance of progesterone receptors alone or in association with estrogen receptors in human breast cancer. Tumori 70: 159–164, 1984
Coradini D, Scavone GF, Cappelletti V, Miodini P, Granata G, Di Fronzo G: Assessment of the prognostic relevance of PgR in addition to ER in node negative breast cancer patients. Abstract: International Congress on Endocrinology and Malignancy, Rome, 22–27 April 1986. Anticancer Res 6: 373, 1986
Kohail HM, Elias EG, El-Nowiem SA, Bashirelahi N, Didolkar MS, Reed WP: A multifactorial analysis of steroid hormone receptors in stage I and II breast cancer. Ann Surg 201: 611–617, 1985
Caldarola GL, Volterrani P, Caldarola B, Lai M, Jayme A, Gaglia P: The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: a multifactorial analysis. Eur J Cancer Clin Oncol 22: 151–155, 1986
Thorpe SM, Rose C, Rasmussen B, King WJ, De Sombre ER, Blough RM, Mouridsen HT, Rossing N, Andersen KW: Steroid hormone receptors as prognostic indicators in primary breast cancer. Breast Cancer Res Treat 7 (Suppl): 91–99, 1986
Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981
von Maillot K, Horke W, Prestele H: Prognostic significance of the steroid receptor content in primary breast cancer. Arch Gynecol 231: 185–190, 1982
Kaufmann M, Klinga K: Mögliche prognostische Kriterien zur Therapie-Verbesserung beim primären Mammakarzinom. Geburtsh u Frauenheilk 42: 501–509, 1982
Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JL: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19: 1381–1387, 1983
Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gomez F: The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Cancer 57: 1171–1180, 1986
Fisher B, Redmond CK, Wickerham DL, Rockette HE, and Brown A, with the contribution of Allegra J, Bowman D, Plotkin D, Wolter J and other NSABP investigators: Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant therapy. Breast Cancer Res Treat 3: 355–365, 1983
Howell A, George WD, Crowther D, Rubens RD, Bulbrook RD, Bush H, Howat JMT, Sellwood RA, Hayward JL, Fentiman IS, Chaudary M: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for breast cancer. Lancet ii: 307–311, 1983
Pascual MR, Macias A, Moreno L, Lage A: Factors associated with prognosis in human breast cancer. V. The simultaneous use of estrogen and progesterone receptor measurements for prediction of short-term relapse. Neoplasma 32: 247–256, 1985
Bonadonna G, Valagussa R, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95–117, 1985
Padmanabhan N, Howell A, Rubens RD: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet ii: 411–415, 1986
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Raemaekers, J.M.M., Beex, L.V.A.M., Pieters, G.F.F.M. et al. Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: The role of adjuvant chemotherapy. Breast Cancer Res Tr 9, 191–199 (1987). https://doi.org/10.1007/BF01806379
Issue Date:
DOI: https://doi.org/10.1007/BF01806379